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Gunjan Bisht1*, Sagar Rayamajhi2, Biplab KC2, Siddhi Nath Paudel2, Deepak Karna2 and Bhupal G. Shrestha2Abstract: Novel magnetic composite nanoparticles (MCPs) were successfully synthesized by ex situ conjugation of
synthesized ZnO nanoparticles (ZnO NPs) and Fe3O4 NPs using trisodium citrate as linker with an aim to retain key
properties of both NPs viz. inherent selectivity towards cancerous cell and superparamagnetic nature, respectively,
on a single system. Successful characterization of synthesized nanoparticles was done by XRD, TEM, FTIR, and VSM
analyses. VSM analysis showed similar magnetic profile of thus obtained MCPs as that of naked Fe3O4 NPs with
reduction in saturation magnetization to 16.63 emu/g. Also, cell viability inferred from MTT assay showed that MCPs
have no significant toxicity towards noncancerous NIH 3T3 cells but impart significant toxicity at similar
concentration to breast cancer cell MDA-MB-231. The EC50 value of MCPs on MDA-MB-231 is less than that of
naked ZnO NPs on MDA-MB-231, but its toxicity on NIH 3T3 was significantly reduced compared to ZnO NPs. Our
hypothesis for this prominent difference in cytotoxicity imparted by MCPs is the synergy of selective cytotoxicity of
ZnO nanoparticles via reactive oxygen species (ROS) and exhausting scavenging activity of cancerous cells, which
further enhance the cytotoxicity of Fe3O4 NPs on cancer cells. This dramatic difference in cytotoxicity shown by the
conjugation of magnetic Fe3O4 NPs with ZnO NPs should be further studied that might hold great promise for the
development of selective and site-specific nanoparticles.
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cytotoxicity, MDA-MB-231, NIH 3T3Background
With novel approaches of cancer treatment being exten-
sively researched in order to mitigate prime limitations of
current approved therapeutics—nonspecificity and nonse-
lective toxicity—development of targeted and selective
cancer therapy has paved its way as a promising tool for
next-generation cancer therapeutics by exploiting proper-
ties of specific binding like ligand-receptor binding,
antigen-antibody mediated immune therapy etc. Targeted
nanoparticles (NPs) also provide more therapeutic benefits
besides specificity and specific localization like high* Correspondence: gunjan.thapa@ku.edu.np; gunjanbisht31@gmail.com
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the Creative Commons license, and indicate ifpayload, multidrug conjugation, easy tuning of release kin-
etics, selective localization, and bypass of multidrug resist-
ance mechanism [1].
Ferrite magnetic NPs (Fe3O4 NPs) are of particular
interest in biomedicine from hyperthermia application [2]
to targeted therapy and drug delivery [3] because of its
superparamagnetic behavior. Unlike strong ferromagnetic
substances, they show linear dependence of magnetization
with external magnetic field in the same direction with
low maximum magnetization, a characteristic property of
paramagnetism. But, the magnetic moment is four to ten
times more than that of normal paramagnetic substances,
hence considered as superparamagnetic [4]. This property
allows Fe3O4 NPs to be used as effective vector for tar-
geted drug therapy under the application of external field.is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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physiological pH limiting its direct application which,
nonetheless, can be overcome by biocompatible surface
coating [3, 5]. But, at the same time, coating of Fe3O4 NPs
with biocompatible nonmagnetic substance affects
magnetization of the particle because of surface spin dis-
order, formation of dead magnetic zone, etc. which is
strongly influenced by thickness and chemical compos-
ition of modifier [6]. Hence, tuning of modifier content
for maintaining therapeutically significant magnetization
value is very important for drug delivery application.
Another important nano-sized particle for cancer ther-
apy is ZnO which has an inherent capacity to induce
apoptosis in cancer cells while rendering very less toxic
effect towards normal proliferating cells [7, 8]. Actual
mechanism of this behavior is still not clear, but various
arguments have been postulated; most supported being
selective uptake of ZnO nanoparticles (ZnO NPs) [9]
due to high expression of membrane anionic phospho-
lipids on cancerous cells [10] imparting zinc-related ions
disequilibrium inducing reactive oxygen species (ROS)
[11, 12]. Nonetheless, this selectivity of ZnO NPs acts as
promising tool for cancer treatment.
Since ZnO itself is biocompatible [13] and can act as a
selective anticancer agent, conjugation of magnetic NPs
with zinc oxide NPs could make novel therapeutically im-
portant compound. Recent research paper [14] has men-
tioned the synthesis of core-shelled ZnO-Fe3O4 NPs with
molar ratios of Fe3O4 NPS to ZnO at 1:1, 1:10, and 1:20
which shows consecutive reduction of magnetization
upon increasing ZnO proportion, being least reduced for
1:1. Although ample study on synthesis of ZnO-ferrite
composite can be found as mentioned, there is still dearth
on cytotoxicity study of such composite for possible
cancer therapy. Hence, we tried to analyze the cytotoxic
profile of this nanocomposite while still retaining




Ferrous sulfate heptahydrate (FeSO4·7H2O), ferric chlor-
ide hexahydrate (FeCl3·6H2O), ammonium hydroxide
(NH4OH), zinc acetate dihydrate (Zn(CH3COO)2·2H2O),
sodium hydroxide (NaOH), trisodium citrate, methanol
(CH3OH), and ethanol (C2H5OH) are of analytical grade
purchased from Sigma-Aldrich and Amresco (USA).
Synthesis of Magnetic Fe3O4 NPs
FeSO4·7H20 (0.5 M) solution was mixed to FeCl3·6H2O
(0.5 M) at 1:1 molar ratio in a conical flask placed on a
magnetic stirring hot plate. NH4OH (1.5 M) was then
added dropwise to iron solution maintained at 70 °C with
vigorous magnetic agitation. Thus, precipitated black-colored particles were then filtered, washed with deionized
water and ethanol, and then oven dried at 60 °C overnight.
The dried particles were finally collected by magnetic
separation.
Synthesis of ZnO NPs
NaOH 0.25 M was added dropwise to 0.05 M zinc
acetate maintained in a conical flask under vigorous
mechanical agitation at room temperature; the cloudy
viscous sediment thus obtained was filtered using vac-
uum filtration, dried overnight at 50 °C, and calcined at
200 °C for 2 h in a muffle furnace to obtain white fine
powdered ZnO.
Conjugation to Form MCPs
Ex situ conjugation approach as described by Shal and
Jafari [14] was used to make the nanocomposite; 0.05 g of
Fe3O4 NPs was dispersed in 0.05 M trisodium citrate solu-
tion prepared in 10 mL distilled water via shaking over-
night at room temperature. Then, trisodium citrate-coated
Fe3O4 NPs were washed with distilled water thrice and
separated magnetically. Finally, 0.05 g of ZnO NPs was
then added in a solution of trisodium citrate-coated Fe3O4
NPs resuspended on distilled water (pH 3.5 acidified by
acetic acid) and stirred for 24 h at room temperature.
Hence, formed magnetic composites were then separated
magnetically, washed several times with distilled water,
and dried at room temperature.
Characterization
X-ray diffraction (XRD), transmission electron microscopy
(TEM), and vibrating sample magnetometry (VSM) were
carried out at IIT, Roorkee, India. XRD spectra were re-
corded at 0.154 nm wavelength (λ) of Cu-kα radiation using
Rigaku-Geiger diffractometer with a range of 2θ from 5° to
80°. Phase identification and crystallographic planes were
determined by comparing peak positions with reference
JCPDS (Joint Committee on Powder Diffraction Standards)
file. Particle size was computed using Scherrer’s equation:
D =Kλ/βcosθ, where K = 0.9 is the shape factor, β is the full
width at half maxima (FWHM) in radians, and θ is the
Bragg’s angle [15]. For TEM analysis, required volume of
sample was sonicated in acetone (1%, w/v) and applied over
carbon-coated copper grid. TEM images were recorded at
×10K magnification and 0.2-μm scale over JEOL 1011
(Tokyo, Japan) at 80 kV. Similarly, Fourier transform infra-
red (FTIR) spectroscopy was performed on powder sam-
ples, and precursors using Shimadzu IR Prestige 21 FT-IR
Spectrometer and corresponding spectrum was generated
using IR-Solution software. VSM was performed using
magnetometer (Princeton EG&G applied research model
155) with maximum current of 30 A, reading number 150,
scan time 900 s at room temperature, and corresponding
data were generated [15].
Bisht et al. Nanoscale Research Letters  (2016) 11:537 Page 3 of 11Cell Culture
Cell lines MDA-MB-231 (human breast adenocarcin-
oma) and NIH 3T3 (murine fibroblast) were revived and
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Life Technologies, USA) added up with 10%
fetal bovine serum (FBS) (Sigma, Germany), 0.5%
antibiotic solution (penicillin/streptomycin (Sigma,
Germany) stabilized with glutamine), 0.5% antimycotic
solution (Amphotericin “B” (Sigma, Germany)), and in-
cubated at 37 °C by supplementing it with 5% CO2.
Methyl thiazolyltetrazolium (MTT) dye (Amresco, USA)
and Trypsin (Amresco, USA) were purchased. Stock
solutions of ZnO NPs and magnetic composite nanopar-
ticles (MCPs) were prepared in Dulbecco’s phosphate
buffer saline (DPBS) (pH 7.4 ± 0.1). Prior to their use,
the solutions were sonicated in water bath sonication for
1 h to prevent particle aggregation.
Cell Viability Assay
MTT assay as mentioned by Adhikari et al. [16] was per-
formed for cell viability assay. Highly proliferating log
phase cells were harvested and seeded in 96-well plates
in DMEM at density of 104 cells per well. The seeded
cells were left for attachment, and after 24 h, the media
was replaced with fresh media supplemented with nano-
particles (ZnO NPs and MCPs) at concentration range
from 200 μg/mL to eightfold serial dilution up to
1.56 μg/mL. After 24 h of treatment with NPs, cells were
washed with DPBS twice and 10 μL of 5 mg/mL MTT
dye was added. It was incubated for 4 h, and absorbance
reading was taken at 570 nm with background subtrac-
tion of 630-nm band-pass filter. Percent cell viability
was expressed as percent relative absorbance of sample
respective to control.
CV Staining
Cultured cells were seeded in 12-well plate at density
of 80,000 cells per well and incubated for 24 h. These
cells were treated with ZnO NPs and MCPs at near
EC50 concentration of 40 and 30 μg/mL, respectively,
and left for 24 h. Nonadherent cells were washed off
using DPBS, and remaining cells were fixed with 4%
paraformaldehyde for 30 min. Then, 0.05% of crystal
violet solution in 20% ethanol was added and left to
stain for 30 min. Finally, excess stain was washed off
using distilled water and observed on phase contrast
microscope at ×10 magnification.
Computation and Statistical Analysis
Cytotoxicity was assessed by measuring cell viability
as a function of relative absorbance, with respect to
control (untreated cells), of dissolved formazan
produced by the conversion of MTT dye by active
mitochondrial dehydrogenase enzymes present inviable cells [17]. Dose-response was plotted under
inbuilt logistic function on Origin 8 given by Eq. (1)
as percent cell death versus logarithmic concentra-
tion. EC50 (measure for Potency), hill slope (P), and
area under the curve (AUC) were assessed for cyto-
toxicity profile. Statistical analysis including ANOVA
was done using inbuilt add-in of Microsoft Excel
2010.
y ¼ A1þ A2−A1
1þ 10 logX0−Xð Þp ð1Þ
where
A1 = bottom asymptote = 0 (fixed)
A2 = top asymptote = 100 (fixed)
LogX0 = mid-value of curve
P = slope factor (hill slope)
Results and Discussion
Characterization
XRD and TEM were performed for the analysis of
size of synthesized particle and study of its morpho-
logical characteristics, respectively. FTIR was used to
verify the conjugation of NPs on composite particle
and to assess its purity. Magnetic properties of parti-
cles were studied by VSM, to verify whether as-
synthesized MCPs retained magnetic property of
Fe3O4 NPs.
XRD and TEM Analysis
X-ray diffraction pattern of synthesized particle is
shown in Fig. 1. ZnO NPs show sharp diffraction
peaks corresponding to hkl values of (100), (002),
(101), and (110) at 2θ values of 31.765, 34.391,
36.195, and 56.606, respectively, suggesting its crys-
talline nature. Similarly, Fe3O4 NPs show diffraction
peaks corresponding to hkl values of (220), (311),
(422), and (553) at 2θ values of 30.07, 35.54, 43.14,
and 62.78, respectively. Average particle size was ob-
tained as 18.67 ± 2.2 nm for ZnO NPs and 14.56 ±
1.53 nm for Fe3O4 using Scherrer’s equation. Corre-
sponding hkl values obtained from PowderX software
indicate crystalline planes of polygonal Wurtzite
structure of ZnO and inverse spinel structure of
magnetite. Five distinct peaks were observed in the
XRD of MCPs which can be correlated with individ-
ual peaks in singly constituted ZnO NPs and Fe3O4
NPs. Since characteristic XRD peaks in individual
particles can be correlated with standard JCPDS file,
with no apparent shift in their position, it suggests
that a heterostructure is formed comprising of both
the particles such that the MCP is crystalline in
nature with no alloying.
Fig. 1 X-ray diffraction patterns of A Fe3O4, B magnetic composite NPs (MCPs), and C ZnO NPs. Dotted lines are used to correlate individual peaks
of as-synthesized Fe3O4 and ZnO NPs with magnetic composite nanoparticles while values corresponding to miller indices (hkl values) are labeled
for peaks between 2θ values of 20°–80°
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1.2 nm from Scherrer’s equation with narrow distribution
size. No any other peaks besides ZnO and Fe3O4 suggest
that no impurities are present. TEM image in Fig. 2
shows morphological characteristic of particles which isFig. 2 TEM images of ZnO NPs, FNPs (Fe3O4 NPs), and MCPs with histogra
composite on nanoscale as suggested by XRD spectra comprising both NPconsistent with XRD result being narrowly distributed
and crystalline in nature. TEM image of MCPs shows
increase in size to average 44 nm from core size of aver-
age 14 nm Fe3O4 NPs which clearly illustrates binding
of ZnO NPs via trisodium citrate.m showing relative size distribution. This illustrates formation of
s
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Figure 3 shows FTIR spectrum of particles from 4000 to
400 cm−1. Characteristic peaks of metal oxide were
observed at 410 and 545 cm−1 corresponding to vibra-
tional mode of Zn–O and Fe–O bonds, respectively.
These peaks are present in MCPs, as well as individually
in ZnO and Fe3O4 nanoparticles. Peaks observed in
between 1200 and 1600 cm−1 are due to symmetric and
asymmetric stretching of COO− bond which is observed
to be sharper in case of asymmetric stretching of COO−,
due to superposition of out of plane O–H vibration.
O–H bond occurs due to physical adsorption of water
on nanoparticle. These peaks corresponding to O–H
and COO− vibration along with characteristic peak
for Zn–O and Fe–O impute that MCPs comprising ofFig. 3 FTIR spectrum of A ZnO NPs, B trisodium citrate, C Fe3O4 NPs, and D
Characteristic peaks of metal oxide were observed at 410 and 545 cm−1 co
respectively. Peaks corresponding to 1200–1600 cm−1 in ZnO NPs are of sy
peaks of both ZnO and Fe3O4 NPs are also observed in MCPs signifying suZnO and Fe3O4 have formed after sodium citrate had
been grafted on the surface of Fe3O4 due to the reaction
between hydroxide groups on Fe3O4 and carboxylate
anion of sodium citrate [18, 19]. Considerable decrease in
FTIR peaks to that of trisodium citrate in MCPs further
verifies that the sample has almost no impurities.
VSM Analysis
Figure 4 shows the magnetization curve of as-
synthesized Fe3O4 NPs and MCPs versus applied
magnetic field (H) between −10 and +10 kOe. For as-
synthesized Fe3O4 NPs, the saturation magnetization
(Ms) is 47.22 emu/g which is reported to vary as a
function of particle size and surface disorder [14, 20].
Similarly, the saturation magnetization of MCPs ismagnetic composite NPs (MCPs) from 4000 to 300 cm−1.
rresponding to vibrational mode of Zn–O and Fe–O bonds,
mmetric and asymmetric stretching of COO− bond. These significant
ccessful conjugation
Fig. 4 Magnetization curves measured at room temperature for A Fe3O4 NPs and B magnetic composite NPs (MCPs) between −10 and +10 kOe
applied magnetic field. Obtained result shows that MCPs have retained superparamagnetic behavior with decrease in saturation magnetization
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lower Ms which is attributed to the presence of non-
magnetic ZnO shell on the surface of Fe3O4 through
(i) interaction of surface atoms of magnetite with
nonmagnetic layer of ZnO [20] and (ii) surface de-
fects and strain in nanocomposite [21].
The remanence of as-synthesized Fe3O4 NPs and
MCPs nanoparticles are 0.596 and 0.227 emu/g, respect-
ively. Both possess negligible remanence at room
temperature showing their typical superparamagnetic
behavior. The coercivity of MCPs is obtained to be
62.90 Oe while that in as-synthesized Fe3O4 NPs is
64.17 Oe. This decrease in coercivity is attributed to de-
crease in inter-particle interactions and magnetoelastic
anisotropy due to stress resulting from coating of mag-
netic core with ZnO shell [21]. All in all, MCPs have
retained superparamagnetic behavior as compared to as-
synthesized Fe3O4 NPs.
Cytotoxicity Study
Percent cell death computed from percent viability was
plotted against logarithmic concentration of ZnO NPs
and MCPs for MDA-MB-231 under inbuilt dose-
response function of Origin 8. The fitted graph was
shown in Fig. 5 with Adj. R2 0.91 along with percent cell
death for NIH 3T3 cell line. EC50 value of ZnO NPs
was found to be at 38.44 μg/mL whereas for MCPs, it
was 31.29 μg/mL. This shows higher potency of MCPs
compared to the ZnO NPs alone. Since only potency isnot sufficient to describe efficiency of the drug, other pa-
rameters like hill slope and area under the curve were
computed and compared to further illustrate advantage
of the MCPs over naked ZnO NPs.
Hill slope (p value) for MCPs was 1.21 ± 0.26 and that
of ZnO alone was 3.24 ± 1.05. Though the value is re-
duced, it is still positive and greater than 1 which signi-
fies strong cooperativity between MCPs and cell death.
This reduction may be particularly important for clinical
application as steep dose-response might pose challenges
in cases of low compliance and unfavorable pharmacoki-
netic profile [22].
The toxicity of ZnO NPs on NIH 3T3 significantly dif-
fers from that of MDA-MB-231 (p value < 0.05; two-
factor ANOVA at α = 0.05). ZnO NPs show less toxicity
on NIH 3T3 above concentration 50 μg/mL than that of
MDA-MB-231 whereas below concentration 50 μg/mL,
they retain certain toxicity. This, however, has been
completely reduced in case of MCPs. Up to 100 μg/mL,
the toxicity of MCPs on NIH 3T3 was found to be dose
independent (Pearson’s r = −0.14) and very low. Given
that selective killing of ZnO NPs between cancerous and
noncancerous cells has been already quoted [7] and
similar findings in our result also support this behavior
[23], our synthesized MCPs show preferentiality between
cancer and noncancerous cell. However, the further de-
crease in toxicity in NIH 3T3 (p value <0.05) in com-
parison to ZnO NPs elevate this effect. This may be
because of less ZnO moieties on surface of MCPs
Fig. 5 Dose-response curve of ZnO NPs (a) and MCPs (b) on cancer cell line MDA-MB 231 (Adj. R2 = 0.91) and cytotoxicity plot ± SD of same
agents on noncancerous cell NIH 3T3. Both agents show concentration independent and very less cytotoxicity on NIH 3T3 in comparison to
dose-dependent strong response towards cancer cell (MDA-MB-231). This inherent selectivity of ZnO NPs, however, was found to be synergistic-
ally enhanced in MCPs with high potency (EC50 31.29 μg/mL for MCPs and 38.44 μg/mL for ZnO only) and significant hill slope (P) 1.21
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because of smaller particle size of ZnO facilitating more
uptake initially showing certain toxicity to NIH 3T3.
But, this should also affect cancer cell line in similarfashion which is seen in the decrement of hill slope in
dose-response curve of MCPs.
Area under the relative viability curve (AUC), a par-
ameter that combines efficacy and potency into single
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(relative cell death) at all tested dose (concentrations)
for ZnO NPs and MCPs on both cell lines [24] where
higher AUC value corresponds to higher activity for cell
death. AUC provides the robust measure for response
when single drug is compared between various cell lines
at the same concentration range. Difference in AUC for
particular drug between cancer and normal cell is of par-
ticular importance for clinical purpose, and our results
show that difference in AUC for MCPs between MDA-
MB-231 and NIH-3T3 is 253.68 which is more than that
of ZnO NPs, 131.45, for concentration range, 25 to
200 μg/mL as represented in Fig. 6. This greater differ-
ence in AUC, higher potency, and less toxicity towards
normal cell make MCPs clinically significant compound
for therapeutic use.
It should be noted that, from our XRD and FTIR results,
the as-synthesized MCPs contain independent domain of
ZnO and ferrite since no alloying or interaction between
these to disturb their individual characteristic peaks have
been seen. This imputes that the mechanism by which
MCPs exert toxicity must be related with individual activ-
ity of NPs at given condition. Since researches in cytotox-
icity of ZnO NPs show oxidative stress, ionic imbalance,
and induction of apoptosis as major cause for their cyto-
toxicity [25], ROS imparting toxicity must be the probable
route for our synthesized NPs. Ferrite as such is nontoxic
[26], but in the presence of excess H2O2, Fe3O4 NPs can
convert H2O2, a reactive oxygen species to more potent
ROS and increase oxidative stress in cell [27]. So, it can be
hypothesized that in case of MCPs, ZnO induces ROS in-
cluding H2O2 and Fe3O4 NPs utilize these H2O2 as a sub-
strate to produce more potent ROS triumphing over near-
exhausted scavenging activity of cancer cell [28]. This ex-
plains the higher potency of MCPs and similar toxicity
profile as of ZnO. The relative low abundance of ROS/
H2O2 in normal cell compared to cancer cell [28, 29] and
inherent nontoxic nature of ZnO NPs towards noncancer-
ous cells cause MCPs to produce less ROS towards nor-
mal cell which can even be defended by antioxidantFig. 6 Plot of percent cell death ± SD against concentration (μg/mL) of a ZnO
area under the curve (AUC) for measure of drug activitymechanism of cell itself and thus less toxicity, even 100%
cell viability (0% cell death) as seen in Fig. 6.
It is important to note that this cytotoxic result is after
24 h of treatment and might not relate to chronic cyto-
toxic effect. The result of 100% cell viability of our
MCPs in normal 3T3 cell, however, does not guarantee
nontoxicity in the long run. But, nonetheless, the huge
difference between cytotoxicity of our MCPs in cancer
cell and noncancerous cell signifies the preferential cyto-
toxicity of as-synthesized MCPs.
CV Staining Assay
Crystal violet (CV) staining was done to support the re-
sult of cytotoxicity depicted by MTT assay. Crystal violet
dye (hexamethylpararosaniline) is a mixture of violet
rosanilins that stains nucleus deep blue, aiding in their
visualization [30]. Since nonadherent dead cells are re-
moved during the washing process of this assay, cells ob-
served as deep blue, stained by crystal violet, account for
viable cells only. Result of CV staining, as depicted by
Fig. 7, shows reduction of viable cells in case of MCP-
treated MDA-MB-231 cells (B) compared to the un-
treated one (A) and, furthermore, is comparable to ZnO
NP-treated cells (C). This observation is in accordance
with the result of MTT assay corresponding to the cyto-
toxicity of MCPs at EC50 concentration on MDA-MB-
231 and hence verifies the cytotoxicity of MCPs towards
breast cancer cell.
Conclusions
ZnO-Fe3O4 magnetic conjugated NPs retained inherent
selective property of ZnO and magnetic property of
Fe3O4 NPs and showed preferential cytotoxicity towards
breast cancer cell line MDA-MB-231, with no significant
cytotoxicity towards noncancerous NIH 3T3 cell. This
finding suggests that MCPs, at a concentration range of
50–100 μg/ml, could be exploited for further research as
a putative preferential anticancer agent. Also, the dra-
matic enhancement of selectivity shown by the conjuga-
tion of magnetic Fe3O4 NPs with ZnO NPs holds greaterNPs and b MCPs on MDA-MB 231 and NIH 3T3 visually representing
Fig. 7 (See legend on next page.)
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Fig. 7 CV staining images of MDA-MB 231 cells. a Control (untreated) MDA-MB 231. b MCPs treated. c Naked ZnO NPs treated. Cells were treated
with nanoparticles for 24 h at concentration of near EC50 value 30 and 40 μg/mL, respectively, for MCPs and ZnO NPs. Cells were fixed by 4%
paraformaldehyde for 30 min and stained by 0.05%. Crystal violet for 30 min and then subsequently washed with distilled water followed by
microscopic observation at ×10
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property of MCPs can be used to target it to a particular
site of cancerous tissue in our body using external mag-
netic field, while the selectivity property of MCPs can be
used to selectively impart cytotoxicity in cancer cells of
the targeted site, causing no significant harm to the nor-
mal cell around the site. Thus, ZnO-Fe3O4 MCPs can
act as highly selective site-specific advanced NPs for tar-
geted cancer therapy. However, further in-depth research
on chronic toxicity profile of such composite including
ROS production, antioxidant activity profiling, and study
of electronic interaction of NPs is recommended for un-
derstanding detail mechanism behind this significant re-
sult and for possible in vivo application.
Abbreviations
CV: Crystal violet; DMEM: Dulbecco’s modified Eagle’s medium;
DPBS: Dulbecco’s phosphate buffer saline; Fe3O4 NPs: Iron (II III) oxide
nanoparticles; FTIR: Fourier transform infrared; MCPs: Magnetic composite
nanoparticles; MTT: Methyl thiazolyltetrazolium; ROS: Reactive oxygen
species; TEM: Transmission electron microscopy; VSM: Vibrating sample
magnetometry; XRD: X-ray diffraction; ZnO NPs: Zinc oxide nanoparticles
Acknowledgements
Authors acknowledge the Department of Biotechnology, Kathmandu
University, Dhulikhel, Nepal, for providing all the support during the study
period. The authors also acknowledge International Foundation for Science
(IFS) co-financed by the Organization for the Prohibition of Chemical
Weapons (OPCW) for the equipment support purchased under the Grant No.
5580.
Authors’ Contributions
GB and BGS designed the study. GB, SP, and DK carried out the synthesis
and conjugation of NPs along with its characterization (XRD, FTIR, and VSM)
and interpretation of characterization. BKC and SR carried out the handling
of cell lines, maintaining cell culture, MTT assay, CV staining, and data
interpretation along with discussion and conclusion. All authors revised,
approved, and have equal contribution in drafting the final manuscript.
Competing Interests
The authors declare that they have no competing interests.
Author details
1Department of Chemical Science and Engineering, Kathmandu University,
Dhulikhel, Post Box 6250, Kathmandu, Nepal. 2Department of Biotechnology,
Kathmandu University, Dhulikhel, Nepal.
Received: 23 June 2016 Accepted: 14 November 2016
References
1. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging
treatment modality for cancer. Nat Rev Drug Discov 7(9):771–82
2. Arteaga-Cardona F, Hidalgo-Tobón S, Pal U, Méndez-Rojas MÁ (2016)
Ferrites as magnetic fluids for hyperthermia and MRI contrast agents. AIP
Conf Proc 1747(1):0700023. Uribe Madrid SI, Pal U, Kang YS, Kim J, Kwon H, Kim J (2015) Fabrication of
Fe3O4@mSiO2 core-shell composite nanoparticles for drug delivery
applications. Nanoscale Res Lett 10(1):217
4. Mulens V, Morales M, Barber D (2013) Development of magnetic
nanoparticles for cancer gene therapy: a comprehensive review. ISRN
Nanomaterials 2013:1–14
5. Lu Y, Yin Y, Mayers B, Xia Y (2002) Modifying the surface properties of
superparamagnetic iron oxide nanoparticles through a sol gel approach.
Nano Lett 2(3):183–6
6. Issa B, Obaidat IM, Albiss BA, Haik Y (2013) Magnetic nanoparticles: surface
effects and properties related to biomedicine applications. Int J Mol Sci
14(11):21266-305
7. Akhtar MJ, Ahamed M, Kumar S, Khan MM, Ahmad J, Alrokayan SA (2012)
Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells
through reactive oxygen species. Int J Nanomedicine 7:845–57
8. Kołodziejczak-Radzimska A, Jesionowski T (2014) Zinc oxide—from synthesis
to application: a review. Materials 7(4):2833
9. Rasmussen JW, Martinez E, Louka P, Wingett DG (2010) Zinc oxide
nanoparticles for selective destruction of tumor cells and potential for drug
delivery applications. Expert Opin Drug Deliv 7(9):1063–77
10. Abercrombie M, Ambrose EJ (1962) The surface properties of cancer cells: a
review. Cancer Res 22:525–48
11. Song W, Zhang J, Guo J, Zhang J, Ding F, Li L et al (2010) Role of the
dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO
nanoparticles. Toxicol Lett 199(3):389–97
12. Shen C, James SA, de Jonge MD, Turney TW, Wright PF, Feltis BN (2013)
Relating cytotoxicity, zinc ions, and reactive oxygen in ZnO nanoparticle-
exposed human immune cells. Toxicol Sci 136(1):120–30
13. Zhou J, Xu NS, Wang ZL (2006) Dissolving behavior and stability of ZnO
wires in biofluids: a study on biodegradability and biocompatibility of ZnO
nanostructures. Adv Mater 18(18):2432–5
14. Shal AA, Jafari A (2014) Study of structural and magnetic properties of
superparamagnetic Fe3O4-ZnO core-shell nanoparticles. J Supercond Nov
Magn 27(26):1531–8
15. Bisht G, Zaidi MG (2015) Supercritical synthesis of poly (2-
dimethylaminoethyl methacrylate)/ferrite nanocomposites for real-time
monitoring of protein release. Drug Deliv Transl Res 5(3):268–74
16. Adhikari S, Lamichhane B, Shrestha P, Shrestha BG (2015) Effect of invitro
zinc (II) supplementation on normal and cancer cell lines. J Trop 3(1):233–40
17. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Methods
65(1-2):55–63
18. Hong RY, Zhang SZ, Di GQ, Li HZ, Zheng Y, Ding J et al (2008) Preparation,
characterization and application of Fe3O4/ZnO core/shell magnetic
nanoparticles. Mater Res Bull 43(8–9):2457–68
19. Cheng C, Wen Y, Xu X, Gu H (2009) Tunable synthesis of carboxyl-
functionalized magnetite nanocrystal clusters with uniform size. J Mater
Chem 19(46):8782–8
20. Kaiser R, Miskolczy G (1970) Magnetic properties of stable dispersions of
subdomain magnetite particles. J Appl Phys 41(3):1064–72
21. Zhang K, Amponsah O, Arslan M, Holloway T, Sinclair D, Cao W et al (2012)
Magnetic nanocomposite spinel and FeCo core-shell and mesoporous
systems. J Magn Magn Mater 324(12):1938–44
22. Vainstein V, Eide CA, O’Hare T, Shukron O, Druker BJ (2013) Integrating
in vitro sensitivity and dose-response slope is predictive of clinical
response to ABL kinase inhibitors in chronic myeloid leukemia. Blood
122(19):3331
23. Kc B, Paudel SN, Rayamajhi S, Karna D, Adhikari S, Shrestha BG et al (2016)
Enhanced preferential cytotoxicity through surface modification: synthesis,
characterization and comparative in vitro evaluation of TritonX-100
modified and unmodified zinc oxide nanoparticles in human breast cancer
cell (MDA-MB-231). Chem Cent J 10:16
Bisht et al. Nanoscale Research Letters  (2016) 11:537 Page 11 of 1124. Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK (2013)
Metrics other than potency reveal systematic variation in responses to
cancer drugs. Nat Chem Biol 9(11):708–14
25. Manke A, Wang L, Rojanasakul Y (2013) Mechanisms of nanoparticle-
induced oxidative stress and toxicity. Biomed Res Int 2013:15
26. Karlsson HL, Cronholm P, Gustafsson J, Möller L (2008) Copper oxide
nanoparticles are highly toxic: a comparison between metal oxide
nanoparticles and carbon nanotubes. Chem Res Toxicol 21(9):1726–32
27. Winterbourn CC (1995) Toxicity of iron and hydrogen peroxide: the Fenton
reaction. Toxicol Lett 82-83:969–74
28. Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen
peroxide by human tumor cells. Cancer Res 51(3):794–8
29. Gibellini L, Pinti M, Nasi M, De Biasi S, Roat E, Bertoncelli L et al (2010)
Interfering with ROS metabolism in cancer cells: the potential role of
quercetin. Cancers 2(2):1288–311
30. Docampo R, Moreno SNJ (1990) The metabolism and mode of action of
gentian violet. Drug Metab Rev 22(2-3):161–78Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
